drugset / Trial / NCT02665377

Prevention of Akute Kidney Injury, Hearttransplant, ANP

NCT02665377 ↗

Phase 3 Completed 86 enrolled Sahlgrenska University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Prospective, blinded, placebo-controlled trial. Patients: Adult patients (\>18 years of age) undergoing de novo Htx, with a preoperative GFR \> 30ml/min, not receiving an ABO-incompatible organ with an ischemia time of \> 6 hours. A donor age \> 70 years is an exclusion criteria. Intervention: Infusion of h-ANP fore five days, starting at the induction of anesthesia. Outcome: Kidney function, evaluated with serum creatinine day 1-7 and kidney clearance, 4-5 Days after Htx plus after 3 and 12 months.

Timeline

Start
2016-09-25
Primary completion
2022-01-08
Completion
2022-01-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator ANP Peptide 50 unknown —

Indications